Managing Unusual Sensory Experiences using a new treatment manual, in people who are experiencing psychosis for the first time

Not Applicable

Completed

• Conditions: Treatment of hallucinations in people with Psychosis; Mental and Behavioural Disorders

• Registration Number: ISRCTN16793301
• Lead Sponsor: Cumbria Northumberland Tyne and Wear NHS Foundation Trust

Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35577470/ (added 18/05/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38678686/ (added 29/04/2024)

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-24
• Study Completion: 2022-10-31
• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

Patients:
1. In contact with Early Intervention in Psychosis (EIP) services
2. Have an identified CPN acting as their care coordinator
3. Meet ICD-11 criteria for schizophrenia, schizoaffective disorder, or entry criteria for an EIP service
4. Have a history of auditory hallucinations for at least four weeks
5. Aged =16 years
6. Consider their hallucinations as a main difficulty, and would like to receive an intervention specifically for hallucinations
7. Have the capacity to provide informed consent
8. Judged by their clinician to be clinically stable for the preceding 4 weeks
9. Individuals on antipsychotic treatment, and those who decline to take medication, will be included, as long as no medication changes have occurred in the previous month (i.e., having started or stopped antipsychotic medication, or a switch to or from Clozapine).

Staff involved in the trial delivery will be asked to help evaluate the training, supervision, and therapy process. These are NHS staff, offering the MUSE treatment. However, the main aspect of feasibility is focussed on the trial and so these details are reported here.

Exclusion Criteria

1. Hallucinations/psychosis with a known biological basis
2. Insufficient command of English to complete the study procedures
3. Intellectual disability, or severe cognitive dysfunction affecting the ability to provide fully informed consent to participate
4. A primary diagnosis of substance misuse/dependency
5. Currently engaged in CBTp or received CBTp in the past 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified